LENZ Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that LENZ Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($16.70M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($14.91M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($14.91M) | Jul 30, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($14.62M) | May 7, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($14.62M) | Jul 30, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($14.62M) | Nov 5, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($10.22M) | Nov 5, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($10.25M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($10.25M) | Jul 30, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.65M) | May 7, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($16.65M) | Jul 30, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($16.65M) | Nov 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($18.88M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($14.73M) | Aug 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($14.73M) | Nov 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.67M) | May 8, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($12.67M) | Nov 6, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($12.67M) | Aug 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($24.68M) | Nov 13, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($25.94M) | Nov 13, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($18.89M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($16.86M) | Jul 30, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($16.93M) | May 7, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($12.95M) | Nov 5, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($14.35M) | Jul 30, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($16.09M) | May 7, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($19.87M) | Nov 6, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($14.96M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.62M) | May 8, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($26.15M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($26.78M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($25.96M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($14.60M) | Nov 9, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($17.53M) | Aug 11, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($9.37M) | May 12, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.76M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($1.29M) | Aug 12, 2021 |